Zura Bio (STU:94E) EPS (Basic) : €-0.64 (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Zura Bio EPS (Basic)?

Zura Bio's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was €-0.18. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.64.

Zura Bio's EPS (Diluted) for the three months ended in Mar. 2025 was €-0.18. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.64.

Zura Bio's EPS without NRI for the three months ended in Mar. 2025 was €-0.18. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -0.59.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Zura Bio EPS (Basic) Historical Data

The historical data trend for Zura Bio's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio EPS (Basic) Chart

Zura Bio Annual Data

Trend

Mar22

Dec23

Dec24

EPS (Basic)

-1.92

-0.57

Zura Bio Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EPS (Basic)	Get a 7-Day Free Trial									-0.02	-0.16	-0.23	-0.08	-0.18

Zura Bio EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Zura Bio's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-50.045	-	0)	/	75.071
	=	-0.67

Zura Bio's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-16.134	-	0)	/	92.964
	=	-0.17

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.64

Zura Bio (STU:94E) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Zura Bio EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Zura Bio's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Zura Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (STU:94E) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

ZURA:USA

Address

1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014

Website

https://www.zurabio.com

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Zura Bio Headlines

No Headlines